Organization: Business Development Bank of Canada

Trillium Therapeutics signs pact with Genentech

Trillium Therapeutics Inc has entered into an agreement with biotech giant Genentech Inc, San Francisco, to develop and commercialize its technology in the area of protein therapeutics. The exact nature of the technology and the terms of the agreement were not disclosed. The agreement will provide privately held Trillium with an upfront payment, research funding…

Cytochroma secures $12-million private financing

Kingston ON-based Cytochroma Inc has closed a $12-million private equity financing to advance its R&D of therapeutics based on cytochrome P450-based metabolism. The Business Development Bank of Canada’s Venture Capital Division is the lead investor, with participation from Novo A/S (Denmark), GeneChem Technologies Venture Fund LP, Canadian Medical Discoveries Fund and Working Ventures Canadian Fund…

IatroQuest receives $4.8 million in financing

IatroQuest Corp has received a $4.8-million private placement to further develop its Bio-Alloy technology platform for the detection of biological and chemical agents. The financing was provided by Investissement Desjardins ($1.5 million), Business Development Bank of Canada ($1.5 million) T2C2 Bio 2000 ($1 million) and several private investors ($800,000). IatroQuest is a spin-off of the…

NeuroMed raises $17 million to further clinical trials

NeuroMed Technologies Inc, Vancouver, has bucked the cooling trend in biotechnology financing raised $17 million to take its pain compounds up to the beginning of Phase II clinical trials. Its R&D into neur-onal calcium blockers aims to develop alternative painkillers to morphine and neuroprotective drugs for stroke. The second-round private financing was provided by GrowthWorks…